Options
Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study
Author(s)
Date Issued
2012-12
Date Available
2013-11-12T09:42:57Z
Abstract
Background: Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30%
of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically
significant depression. Effective and timely detection of depression is crucial to ensuring
appropriate treatment and support. However, little is known about how clinical nurse
specialists identify patients at risk of developing interferon-alpha-induced depression, and
monitor those receiving antiviral treatment for the occurrence of depression.
of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically
significant depression. Effective and timely detection of depression is crucial to ensuring
appropriate treatment and support. However, little is known about how clinical nurse
specialists identify patients at risk of developing interferon-alpha-induced depression, and
monitor those receiving antiviral treatment for the occurrence of depression.
Type of Material
Journal Article
Publisher
Elsevier
Journal
International Journal of Nursing Studies
Volume
49
Issue
12
Start Page
1480
End Page
1488
Copyright (Published Version)
2012 Elsevier Ltd.
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
File(s)
Loading...
Name
Hepgul_&_Kodate_et_al_2012.pdf
Size
491.3 KB
Format
Adobe PDF
Checksum (MD5)
b24bfb1ac027fba57ede2aaa55d2ec49
Owning collection